SARS-CoV-2 Drug Repurposing Candidates

Case Study

NIH NCATS Case Study: Using Accelerated Screening Research for SARS-CoV-2 Drug Repurposing Candidates

SARS-CoV-2 Drug Repurposing Candidates


Drug Repurposing can be an effective way to identify treatments for diseases, especially when time is of the essence.

Research scientists at National Center for Advancing Translational Sciences (NCATS), a part of the NIH, embarked on a drug repurposing strategy as the quickest route to generating data that would help the pharma industry drive towards an effective treatment for the COVID-19 virus.

Find out how in a matter of months the NCATS team was able to screen 3,384 molecular entities and narrow them down to a field of 25 quality "hits" capable of disrupting SARS-Cov-2 S1 protein:ACE2 receptor binding in this case study.